Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
| 12/21/2023 | $11.00 | Buy | BTIG Research |
| 10/13/2023 | $8.00 | Outperform | Oppenheimer |
| 8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
DEFA14A - Ovid Therapeutics Inc. (0001636651) (Filer)
DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberger will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da
Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform
B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d